Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) is a genomic medicine company whose news flow centers on clinical data, regulatory interactions, collaborations and financial updates across its neurology‑focused pipeline. Company announcements emphasize investigational programs in Fabry disease, chronic neuropathic pain and prion disease, along with progress in its zinc finger epigenetic regulation and AAV capsid platforms.
A major theme in recent SGMO news is the development of isaralgagene civaparvovec (ST‑920), a wholly owned investigational gene therapy for adults with Fabry disease. Press releases detail topline and updated results from the registrational Phase 1/2 STAAR study, including positive mean annualized estimated glomerular filtration rate (eGFR) slopes at 52 and 104 weeks, stability of cardiac endpoints, biomarker trends and quality‑of‑life measures. Regulatory milestones, such as FDA agreement to use eGFR slope as an endpoint for an accelerated approval pathway and acceptance of a rolling Biologics License Application (BLA) submission, are also key subjects.
Investors following SGMO news can also track developments in the Phase 1/2 STAND study of ST‑503 for intractable pain due to small fiber neuropathy, including FDA Fast Track Designation, site activation and recruitment updates. Additional releases describe preclinical and regulatory progress for ST‑506 in prion disease, as well as business development activities like the capsid license agreement with Eli Lilly and Company and other collaboration‑related revenues.
Quarterly earnings releases and conference call announcements provide context on Sangamo’s operating expenses, cash position and strategic focus on a neurology‑oriented genomic medicine business. For readers interested in SGMO, this news page aggregates these clinical, regulatory, partnership and financial disclosures in one place, making it easier to follow the company’s reported milestones over time.
Sangamo Therapeutics (Nasdaq: SGMO) has presented detailed data from its registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 dosed patients.
Key highlights include stable cardiac function, sustained α-Gal A activity for up to 4.5 years, and successful withdrawal of all 18 patients from Enzyme Replacement Therapy (ERT). The therapy showed a favorable safety profile without requiring preconditioning, with mostly grade 1-2 adverse events.
Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway. The therapy has received multiple regulatory designations, including Fast Track and RMAT from FDA.
Sangamo Therapeutics (Nasdaq: SGMO) reported significant progress in Q2 2025, highlighted by positive topline results from their registrational STAAR study for Fabry disease treatment. The study showed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52-weeks across all 32 patients, supporting potential FDA Accelerated Approval.
Financial results showed a reduced net loss of $20.0 million ($0.08 per share) compared to $36.1 million in Q2 2024. Revenues increased to $18.3 million, primarily from Eli Lilly's upfront license payment. Cash position stands at $38.3 million, expected to fund operations into Q4 2025.
The company initiated its first clinical site for the Phase 1/2 STAND study in chronic neuropathic pain, with first patient dosing expected fall 2025. Sangamo plans to submit a BLA for its Fabry disease treatment by Q1 2026.
Sangamo Therapeutics (Nasdaq: SGMO), a genomic medicine company, has scheduled its second quarter 2025 financial results release for Thursday, August 7, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.
Participants can register and access the call through a provided link, with a recommended join time of 10 minutes before the event. The webcast will be available in the Investors and Media section of Sangamo's website, with a replay accessible after the call.
[]Sangamo Therapeutics (Nasdaq: SGMO) announced positive topline results from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease. The study demonstrated a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks across all 32 patients, which will serve as the primary basis for FDA approval.
Key highlights include maintained elevated α-Gal A activity for up to 4.5 years, successful withdrawal of all 18 patients from enzyme replacement therapy (ERT), and significant improvements in quality of life scores. The therapy showed a favorable safety profile without preconditioning requirements. Sangamo plans to submit a Biologics License Application (BLA) in Q1 2026 under the Accelerated Approval pathway.
Sangamo Therapeutics (NASDAQ: SGMO) has announced a change in timing for its first quarter 2025 earnings call. The call has been rescheduled from 4:30 p.m. Eastern to 6:30 p.m. Eastern on Monday, May 12, 2025. The registration and access details remain unchanged, with participants able to join via the same previously provided link.
Attendees are encouraged to join 10 minutes before the start time and can choose between dialing in with a provided number and passcode or using a dial-out option. The webcast will be available through the Investors and Media section of Sangamo's website, with a replay accessible after the call.
Sangamo Therapeutics (NASDAQ: SGMO), a genomic medicine company, has scheduled its first quarter 2025 financial results release for Monday, May 12, 2025, after market close. The company will host a conference call at 4:30 p.m. Eastern the same day to discuss financial results and provide business updates.
Participants can register and access the call through a provided link, with a recommendation to join 10 minutes before the start. They can either dial in with a unique passcode or use the dial-out option. A webcast will be available on Sangamo's website in the Investors and Media section, with a replay accessible afterward.
Sangamo Therapeutics (NASDAQ: SGMO) has achieved key milestones for its Fabry disease gene therapy candidate ST-920 (isaralgagene civaparvovec). All patients in the Phase 1/2 STAAR study have completed the FDA-required 52-week follow-up for Accelerated Approval pathway. Preliminary analysis across 32 dosed patients shows continued positive mean eGFR slope, with the therapy being well-tolerated. A productive Type B CMC meeting with the FDA has provided a clear pathway to the planned BLA submission in Q1 2026.
The company expects a pivotal data readout by end of Q2 2025, with potential approval and commercial launch as early as H2 2026. Sangamo is currently in discussions with EMA regarding potential European approval and engaging in business development negotiations for Fabry commercialization.
Summary not available.